IMUNON, Inc. announced on May 8, 2025, that the first trial site has been initiated for its Phase 3 pivotal study, OVATION 3, for IMNN-001. This lead candidate is being developed for the treatment of women with newly diagnosed advanced ovarian cancer.
The initial site is Washington University School of Medicine, and IMUNON is actively working to initiate additional trial sites and enroll study participants. This marks a significant step forward for the IMNN-001 development program, which aims to bring a novel IL-12 immunotherapy to patients.
IMNN-001 is the first and only immunotherapy to demonstrate a meaningful overall survival benefit in a Phase 2 trial for advanced ovarian cancer, a disease area that has seen limited changes in standard of care for over 25 years. New data from the Phase 2 OVATION 2 Study will also be highlighted in an oral presentation at the 2025 ASCO Annual Meeting.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.